Rhythm Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
IMCIVREE’s U.S. launch for acquired HO is underway, with expansion planned in Europe and Japan. Key pipeline updates include mid-year PWS data and phase III studies for new agents. The company is focused on rare MC4R pathway diseases, with strong cash reserves and a long-term vision for global leadership.
-
IMCIVREE received FDA approval for acquired hypothalamic obesity, supported by phase III data showing significant BMI and hunger reductions. The launch targets a US population of about 10,000, with expanded sales and patient support teams, and ongoing efforts to secure broad payer coverage and international approvals.
-
The phase III EMANATE trial missed its primary endpoint in all four genetic obesity cohorts, but post-hoc analyses revealed significant BMI reductions in genetically confirmed POMC HET and SRC1 patients. High dropout rates and challenges in variant classification informed plans to focus future studies on next-generation MC4R agonists and improved patient selection.
-
The company is advancing therapies for rare obesity disorders via the melanocortin-4 pathway, with a major HO launch pending FDA decision in March and global expansion underway. Next-gen therapies and robust IP aim to extend commercial life, while clinical data in Prader-Willi and genetic obesity support future growth.
-
IMCIVREE is expanding into new indications, with strong clinical data in hypothalamic obesity and promising interim results in Prader-Willi syndrome. Sales growth is driven by BBS, and the company is preparing for a larger HO market with an expanded sales force and robust cash runway.
Fiscal Year 2025
-
IMCIVREE revenues grew 50% year-over-year to $194.8M in 2025, driven by U.S. and international expansion. Regulatory milestones for HO and new geographies are on track for 2026, with increased investment in R&D and commercial operations.
-
Preliminary phase II data in PWS show setmelanotide led to BMI reductions in most patients, with additional improvements in body composition and hyperphagia scores. The drug was well tolerated, and results support advancing to a phase III trial targeting a 5% placebo-adjusted BMI reduction.
-
MC4 pathway targeting continues to show promise in rare and acquired obesity, with setmelanotide demonstrating superior efficacy over GLP-1s in HO. FDA review was extended, providing more time for commercial launch preparation. International markets and next-gen assets are advancing.
-
Q3 revenue grew 54% year-over-year to $51.3M, driven by Imcivree for rare MC4R pathway diseases. The company is preparing for a major U.S. launch in acquired hypothalamic obesity, with strong cash reserves and multiple regulatory milestones expected in the coming quarters.
-
Setmelanotide is poised for launch in acquired hypothalamic obesity, supported by robust infrastructure, expanded teams, and strong payer engagement. Clinical data show consistent, meaningful weight loss and hunger reduction, with high physician interest and a clear strategy for rapid adoption and access.
-
The conference highlighted strong clinical results and expanding market opportunities for rare genetic obesity syndromes, especially BBS and HO. Next-generation MC4R programs are advancing, with regulatory filings in the U.S., Europe, and Japan, and a robust launch strategy underway.
-
Significant progress was highlighted in rare obesity disorders, with setmelanotide advancing in BBS and HO, and next-generation MC4 agonists moving toward Phase III. The HO launch is expected early next year, with growing physician engagement and a focus on payer differentiation.
-
Q2 2025 saw strong revenue growth, positive clinical milestones, and a strengthened balance sheet with a $189M equity raise. IMCIVREE sales expanded in both U.S. and international markets, and regulatory filings for setmelanotide in HO remain on track.
-
Bivamelagon demonstrated robust, dose-dependent BMI reductions in hypothalamic obesity, with efficacy and safety comparable to setmelanotide but with less hyperpigmentation. Compliance challenges were linked to pill size, prompting new formulations ahead of phase III trials.
-
Phase III data in hypothalamic obesity showed robust, consistent BMI reduction and high patient compliance, with a manageable safety profile. Next-generation oral and weekly agents are in development, and expansion into Prader-Willi syndrome is underway. Patent protection and a strong cash position support ongoing and future programs.
-
The company is expanding from rare genetic obesity indications to hypothalamic obesity, with strong phase III results and a robust pipeline including oral and weekly MC4R agonists. Key data readouts for new formulations and a Prader-Willi study are expected by year-end.
-
Regulatory changes are not expected to materially impact operations, and Gentiva integration is progressing well with stable leadership. Expansion in Texas and value-based care are priorities, while M&A activity remains active. Hospice growth is strong, and technology adoption is improving operational efficiency.
-
Q1 2025 saw 45% year-over-year revenue growth, strong global IMCIVREE demand, and robust phase III HO data with a 16.5% BMI reduction. Cash runway extends into 2027, and international expansion continues, with new data presentations and a Q3 FDA filing on track.
-
Phase III results for setmelanotide in acquired hypothalamic obesity showed a 19.8% placebo-adjusted BMI reduction, consistent efficacy across age groups, and a safety profile in line with previous studies. Providers view it as a transformative, targeted therapy for this severe unmet need.
-
The company is advancing therapies for rare genetic and acquired obesity via the MC4 pathway, with Imcivree showing consistent efficacy and expanding into new indications like HO and Prader-Willi. Commercial growth is steady, and next-generation drugs with extended patent life are in development.
Fiscal Year 2024
-
Strong Q4 and full-year 2024 revenue growth was driven by IMCIVREE sales in the U.S. and internationally, with expanded access and a solid cash position supporting pipeline advancement. Key clinical milestones are expected in 2025, including pivotal trial readouts.
-
The company is advancing therapies for rare genetic and acquired obesity, with setmelanotide showing consistent efficacy in both pediatric and adult HO patients. Bardet-Biedl syndrome remains a steady growth driver, and two new pipeline candidates are progressing toward key data readouts in 2024–2025.
-
Rare obesity is addressed as a distinct, multi-disease area with setmelanotide showing strong efficacy in both BBS and HO. Next-generation oral and weekly formulations aim to extend market exclusivity, while global expansion and pipeline development are prioritized for long-term growth.
-
Q3 2024 saw strong revenue growth, driven by expanding U.S. and international sales of Imcivree, robust clinical progress in hypothalamic obesity, and positive real-world data supporting future label expansions. Cash position remains solid, with reduced OpEx guidance and key milestones on track for 2025.
-
Setmelanotide shows strong, consistent efficacy in rare genetic obesity, with a pivotal phase III HO trial fully enrolled and data expected soon. Commercial efforts in BBS are steady, with significant U.S. and European market potential, and HO launch is expected to ramp faster due to higher diagnosis rates.
-
Q2 2024 saw 12% sequential and 52% year-over-year revenue growth, driven by Imcivree sales in the US and Europe, with expanded pediatric approvals and strong progress in clinical trials. Cash position is robust, and guidance for 2024 OpEx and long-term growth remains unchanged.
-
The company is advancing therapies for rare genetic obesity, with setmelanotide showing strong efficacy in hypothalamic obesity and Bardet-Biedl syndrome. Next-generation MC4R agonists and an oral program are progressing, with key data readouts expected in 2025.